Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Karyopharm Therapeut (KPTI)

Karyopharm Therapeut (KPTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 173,751
  • Shares Outstanding, K 115,067
  • Annual Sales, $ 146,030 K
  • Annual Income, $ -143,100 K
  • 60-Month Beta 0.01
  • Price/Sales 1.06
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade KPTI with:

Options Overview Details

View History
  • Implied Volatility 145.50% ( +65.69%)
  • Historical Volatility 142.45%
  • IV Percentile 37%
  • IV Rank 7.33%
  • IV High 975.70% on 12/21/23
  • IV Low 79.81% on 03/15/24
  • Put/Call Vol Ratio 0.07
  • Today's Volume 158
  • Volume Avg (30-Day) 422
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 8,983
  • Open Int (30-Day) 6,965

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.33
  • Number of Estimates 4
  • High Estimate -0.28
  • Low Estimate -0.37
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0800 +36.11%
on 02/22/24
1.7000 -13.53%
on 03/08/24
+0.2000 (+15.75%)
since 02/16/24
3-Month
0.6555 +124.26%
on 01/16/24
1.9500 -24.62%
on 02/06/24
+0.7168 (+95.17%)
since 12/18/23
52-Week
0.6174 +138.10%
on 12/11/23
4.8700 -69.82%
on 04/17/23
-1.9300 (-56.76%)
since 03/17/23

Most Recent Stories

More News
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript

KPTI earnings call for the period ending December 31, 2023.

KPTI : 1.4700 (-2.65%)
Karyopharm Therapeutics: Q4 Earnings Snapshot

Karyopharm Therapeutics: Q4 Earnings Snapshot

KPTI : 1.4700 (-2.65%)
Karyopharm Therapeutics (KPTI) Q3 2023 Earnings Call Transcript

KPTI earnings call for the period ending September 30, 2023.

KPTI : 1.4700 (-2.65%)
Karyopharm Therapeutics: Q3 Earnings Snapshot

Karyopharm Therapeutics: Q3 Earnings Snapshot

KPTI : 1.4700 (-2.65%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

KPTI : 1.4700 (-2.65%)
Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

KPTI : 1.4700 (-2.65%)
Karyopharm to Participate at Upcoming Investor Conferences

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

KPTI : 1.4700 (-2.65%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

KPTI : 1.4700 (-2.65%)
Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...

KPTI : 1.4700 (-2.65%)
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China

- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broadening coverage and...

KPTI : 1.4700 (-2.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States.

See More

Key Turning Points

3rd Resistance Point 1.7465
2nd Resistance Point 1.6833
1st Resistance Point 1.5766
Last Price 1.4700
1st Support Level 1.4067
2nd Support Level 1.3435
3rd Support Level 1.2368

See More

52-Week High 4.8700
Fibonacci 61.8% 3.2455
Fibonacci 50% 2.7437
Fibonacci 38.2% 2.2419
Last Price 1.4700
52-Week Low 0.6174

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar